Table 3.
Case-control studies of the comparison between the PTX-based regimen and the PF regimen in preoperative neoadjuvant chemoradiotherapy
| Institution/ Study Type | Cases | CT | RT | pCR (%) | 3-yr OS (%) | ≥3 Side effect | ||
|---|---|---|---|---|---|---|---|---|
| Total | SC | AC | ||||||
| Cleveland Clinic Foundation [12]/ prospective, non-randomized | 72 | PF | 45 Gy, 1.5 Gy/FX, BID (split course) or 24 Gy postoperative | 27 | 36 | 22 | 36 | Vomiting (1%), mucositis (18%), leucopenia (43%), thrombocytopenia (10%), nephrotoxicity (8%), unplanned hospitalization (25%) |
| 40 | TP | 23 | 50 | 8 | 30 | Mucositis (13%), leucopenia (95%), neuropathy (13%), unplanned hospitalization (48%) | ||
| Duke University [9]/ retrospective | 57 | PF | 45–50.4 Gy, 1.8–2.0 Gy/FX | 40 | – | – | 37 | 24% |
| 52 | TPF | 39 | – | – | 37 | 34% | ||
| Massachusetts General Hospital [33]/ retrospective | 81 | PF | CTV 45 Gy/25FX, GTV 58.5 Gy/25FX (13.5 Gy, 1.5 Gy/FX concomitant boost during the first and second cycles of CT) | 46 | – | – | 39 | 79% |
| 83 | TPF | 37 | – | – | 42 | 80% | ||
Abbreviations: CT chemotherapy, RT radiotherapy, SC squamous cell carcinoma, AC adenocarcinoma, pCR pathologic complete response, OS overall survival, PF cisplatin plus 5-fluorouracil, TP paclitaxel plus cisplatin, TPF paclitaxel plus cisplatin plus 5-fluorouracil